NCT07385079 2026-02-03
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
5 trialsNCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT06611826 2024-09-25
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT04870905 2023-03-06
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting